HR-3906-119
Referred to the House Committee on Appropriations.
Sponsored by André Carson (D-IN)
What it does
This bill would amend the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119-4) to restore approximately $1.18 billion in Defense Health Agency research, development, test, and evaluation funding that was reduced in that law. It would specifically direct that the restored funds support Congressionally Directed Medical Research Programs (CDMRPs) at the same levels and priorities established in the Consolidated Appropriations Act, 2024, including all peer-reviewed research programs and projects listed on pages 311–314 of that act's explanatory statement. The Secretary of Defense would be required to obligate and spend the funds in a way that preserves continuity of ongoing research programs.
Who benefits
Active-duty military personnel and veterans who may benefit from research into combat-related injuries, traumatic brain injury, post-traumatic stress, and other service-connected conditions. Civilian patients who benefit from CDMRP research into diseases like cancer, Alzheimer's, and rare conditions that receive funding through these programs. Academic medical centers, universities, and research institutions that receive CDMRP grants. Scientists and researchers whose projects were disrupted by the funding reduction. Patient advocacy organizations that have historically championed CDMRP funding for specific disease areas.
Who is hurt
Taxpayers who would bear the cost of the approximately $1.18 billion increase in discretionary defense spending. Other federal programs that may face offsetting reductions if Congress seeks to stay within spending caps. The executive branch's flexibility to allocate defense health funds according to its own priorities would be constrained by the bill's directive to follow the 2024 explanatory statement's specific allocations.
Supporters argue
Supporters argue that the CDMRPs fund peer-reviewed, competitively selected research that directly addresses the health needs of service members and veterans — including traumatic brain injury, suicide prevention, and cancer — and that abruptly cutting $1.18 billion mid-cycle disrupts multi-year studies and wastes prior federal investment. They contend that Congress, not the executive branch, holds the constitutional power of the purse and that restoring these funds to their 2024 levels simply enforces the legislative branch's established research priorities for programs with documented health outcomes.
Opponents argue
Opponents argue that the 2025 continuing resolution already set overall defense spending levels through a deliberate legislative process, and that adding $1.18 billion in new spending without offsetting cuts or a pay-for increases the federal deficit. They contend that locking funding to the specific line-item allocations of a prior year's explanatory statement — a non-binding document — is an unusual mechanism that limits the Secretary of Defense's ability to adapt research priorities to emerging needs, and that the executive branch should retain flexibility to direct health research dollars where they are most effective.
Constitutional context
The Appropriations Clause (Art. I, §9, cl. 7) gives Congress exclusive authority to direct how federal funds are spent, and the bill exercises that power by restoring and directing specific defense health expenditures. The bill also implicates the tension between congressional appropriations authority and executive discretion over military spending, a dynamic addressed in Youngstown Sheet & Tube v. Sawyer (1952), which held that the President's power is at its lowest when acting contrary to congressional direction.
Checks and balances
Congress gains authority by restoring and directing specific spending levels; the Secretary of Defense is bound by the bill's mandate to follow 2024 program allocations, reducing executive discretion over these funds.
Historical precedent
Congress has previously used standalone appropriations bills to restore funding cut by continuing resolutions, though directing compliance with a prior year's explanatory statement as a binding funding mechanism is an uncommon approach.